INCY · 8-K · 20261029PR000063

Research and Development Expense

INCYTE CORP · 2026-10-29 · Importance 77 · Surprise 82 · No source text

Third-quarter 2026 GAAP R&D expense was $1.792 billion and non-GAAP R&D expense was $1.746 billion, up 254% and 274%, respectively, year over year. The increase primarily reflected $1.23 billion of upfront consideration for the Vega acquisition, increased investment in latarcibart, and continued advancement of the late-stage development portfolio. Excluding the Vega upfront consideration, GAAP R&D expense increased 11% year over year, primarily due to greater investment in late-stage development assets.

Key facts

• Incyte’s GAAP R&D expense was $1.79 billion in the third quarter of 2026, up 254% year over year. source
• Incyte’s non-GAAP R&D expense was $1.75 billion in the third quarter of 2026, up 274% year over year. source
• Incyte recorded a one-time $1.23 billion IPR&D expense related to its acquisition of Vega Therapeutics in the third quarter of 2026. source
• Excluding the Vega acquisition upfront consideration, Incyte’s GAAP R&D expense increased 11% year over year in the third quarter of 2026. source

Impact estimates